Replies to post #8453 on Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

Assuming the BO includes full rights to VOS...

I'd be happy with $30/sh on Monday, $40/sh after Ph3 data release, $50/sh after FDA approval. There's no model behind that, just what I'd be happy with right now. Let's call it 100m outstanding shares fully diluted at $50/sh puts the BO at $5b. With everything we now know, that doesn't seem like a stretch to me. Big question is whether the future acquirer will want to see adoption first. If so, price goes up...